Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy

YW Chen, K Nagaraju, M Bakay, O McIntyre, R Rawat… - Neurology, 2005 - AAN Enterprises
YW Chen, K Nagaraju, M Bakay, O McIntyre, R Rawat, R Shi, EP Hoffman
Neurology, 2005AAN Enterprises
Objective: To identify stage-specific induction of molecular pathology pathways in Duchenne
muscular dystrophy (DMD). Methods: We performed mRNA profiling using muscles from
fetopsies, infants (aged 8 to 10 months), and symptomatic patients (aged 5 to 12 years) with
DMD, and age-and sex-matched controls. We performed immunohistochemistry to
determine changes at the protein level and protein localization. Results: Activated tissue
dendritic cells, expression of toll-like receptor 7, and strong induction of nuclear factor-κB …
Objective: To identify stage-specific induction of molecular pathology pathways in Duchenne muscular dystrophy (DMD).
Methods: We performed mRNA profiling using muscles from fetopsies, infants (aged 8 to 10 months), and symptomatic patients (aged 5 to 12 years) with DMD, and age- and sex-matched controls. We performed immunohistochemistry to determine changes at the protein level and protein localization.
Results: Activated tissue dendritic cells, expression of toll-like receptor 7, and strong induction of nuclear factor-κB pathways occurred soon after birth in DMD muscle. Two muscle wasting pathways, atrogin-1 and myostatin, were not induced at any stage of the disease. Normal muscle showed accumulation of glycolytic and oxidative metabolism capacity with increased age, but this accumulation failed in DMD. The transforming growth factor (TGF)-β pathway was strongly induced in symptomatic patients, with expression of TGFβ type II receptor and apoptosis signal-regulating kinase 1 proteins on subsets of mature DMD myofibers
Conclusions: Our data show stage-specific remodeling of human dystrophin-deficient muscle, with inflammatory pathways predominating in the presymptomatic stages and acute activation of TGFβ and failure of metabolic pathways later in the disease.
American Academy of Neurology